Trials / Active Not Recruiting
Active Not RecruitingNCT06237257
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The Primary purpose of this study is to evaluate the safety of SHR-1316 plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The second purpose of this study is to evaluate the efficacy and PK traits; The exploratory study is to explore the biomarker 、immunogenicity and so on .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SHR-1316 | SHR-1316（Adebrelimab Injection） |
| DRUG | Cisplatin Injection/Carboplatin Injection | Cisplatin Injection/Carboplatin Injection |
| RADIATION | External Beam Radiotherapy (EBRT)/Brachytherapy | External Beam Radiotherapy (EBRT)/Brachytherapy |
| DRUG | Paclitaxel Injection | Paclitaxel Injection. |
Timeline
- Start date
- 2024-03-20
- Primary completion
- 2024-12-01
- Completion
- 2025-01-01
- First posted
- 2024-02-01
- Last updated
- 2024-12-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06237257. Inclusion in this directory is not an endorsement.